Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Tatum Highlands Medical Associates, PLLC
mi
from
Phoenix, AZ
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Tatum Highlands Medical Associates, PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Arizona Community Physicians
mi
from
Tucson, AZ
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Arizona Community Physicians
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Orange Grove Family Practice
mi
from
Tucson, AZ
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Orange Grove Family Practice
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Mile High Primary Care
mi
from
Aurora, CO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Mile High Primary Care
mi
from
Aurora, CO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Atlanta, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Medical and Procedural Specialists of Illinois
mi
from
Chicago, IL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Medical and Procedural Specialists of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Michigan Avenue Internists
mi
from
Chicago, IL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Michigan Avenue Internists
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research Inc.
mi
from
Chicago, IL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research Inc.
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
West Florissant Internists
mi
from
Bridgeton, MO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
West Florissant Internists
mi
from
Bridgeton, MO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Skyline Medical Center
mi
from
Elkhorn, NE
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Skyline Medical Center
mi
from
Elkhorn, NE
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Prairie Fields Family Medicine
mi
from
Fremont, NE
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Prairie Fields Family Medicine
mi
from
Fremont, NE
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Nevada Family Care
mi
from
Henderson, NV
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Nevada Family Care
mi
from
Henderson, NV
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Diagnostic Center of Medicine
mi
from
Las Vegas, NV
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Diagnostic Center of Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Sunstone Medical Research, LLC
mi
from
Medford, OR
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Sunstone Medical Research, LLC
mi
from
Medford, OR
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Primary Care Associates, PA
mi
from
Anderson, SC
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Primary Care Associates, PA
mi
from
Anderson, SC
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Doctors of Internal Medicine
mi
from
Plano, TX
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Doctors of Internal Medicine
mi
from
Plano, TX
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Southview Medical Group, P.C.
mi
from
Birmingham, AL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Southview Medical Group, P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Achieve Clinical Research
mi
from
Birmingham, AL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Allied Clinical Research
mi
from
Gold River, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Allied Clinical Research
mi
from
Gold River, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Alpine Clinical Research Center
mi
from
Boulder, CO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Alpine Clinical Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Brooksville, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
MD Clinical
mi
from
Hallandale Beach, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Tampa, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Tampa, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Georgia Neurology and Sleep Medicine Associates
mi
from
Suwanee, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Georgia Neurology and Sleep Medicine Associates
mi
from
Suwanee, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Trials
mi
from
Boise, ID
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Trials
mi
from
Boise, ID
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
West Bay Clinical Research
mi
from
Warwick, RI
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
West Bay Clinical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Medical Research South
mi
from
Charleston, SC
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Medical Research South
mi
from
Charleston, SC
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Murray, UT
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Murray, UT
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Alabama Clinical Therapeutics, Llc
mi
from
Birmingham, AL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Alabama Clinical Therapeutics, Llc
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
21st Century Neurology
mi
from
Phoenix, AZ
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
21st Century Neurology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
The Research Center of Southern California
mi
from
Carlsbad, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
The Research Center of Southern California
mi
from
Carlsbad, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
eStudySite
mi
from
Chula Vista, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
eStudySite
mi
from
Chula Vista, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Pacific Research Partners, LLC
mi
from
Oakland, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Pacific Research Partners, LLC
mi
from
Oakland, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Desert Valley Research
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Northern California Clinical Research Center
mi
from
Redding, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Northern California Clinical Research Center
mi
from
Redding, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
mi
from
San Diego, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Neurological Research Institute
mi
from
Santa Monica, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Neurological Research Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Encompass Clinical Research
mi
from
Spring Valley, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials